<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04942834</url>
  </required_header>
  <id_info>
    <org_study_id>Cryo-initial-AF</org_study_id>
    <nct_id>NCT04942834</nct_id>
  </id_info>
  <brief_title>Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation</brief_title>
  <acronym>Cryo-InitialAF</acronym>
  <official_title>Using Cryoballoon Ablation as Initial Treatment for Patients With Persistent Atrial Fibrillation Comparing to Anti-arrhythmic Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the effectiveness and safety of using cryoballoon ablation comparing&#xD;
      with anti-arrhythmic drug therapy as initial treatment for naive patients with persistent&#xD;
      atrial fibrillation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with persistent atrial fibrillation with no history of treatment with&#xD;
      anti-arrhythmic drugs are randomized 1:1 to either an anti-arrhythmic drug or pulmonary vein&#xD;
      isolation using the cryoballoon catheter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment success at 12 months</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Treatment success at 12 months after antiarrhythmic drug (AAD) initiation or ablation utilizing cryoballoon catheter measured by freedom from AF recurrence following a 3-month period after the index ablation or AAD initiation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of serious adverse events</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Rate of serious procedure-related and serious cryoablation system-related reported adverse events through 12 months after the index ablation procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life changes at 12 months measured by AFEQT</measure>
    <time_frame>one year</time_frame>
    <description>The improvement in quality of life between baseline and 12 months after the index ablation procedure or AAD measured by AF Quality of Life Survey (AFEQT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life changes at 12 months measured by SF-12</measure>
    <time_frame>one year</time_frame>
    <description>The improvement in quality of life between baseline and 12 months after the index ablation procedure or AAD measured by 12-Item Short Form Survey (SF-12)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arrhythmia recurrence during blanking period</measure>
    <time_frame>3 months</time_frame>
    <description>atrial tachycardia recurrence rate during the blanking period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to first time cardiovascular hospitalization (month)</measure>
    <time_frame>one year</time_frame>
    <description>time to first time cardiovascular hospitalization after treatment (month)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">286</enrollment>
  <condition>Atrial Fibrillation, Persistent</condition>
  <condition>Arrhythmias, Cardiac</condition>
  <arm_group>
    <arm_group_label>Drug treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>receive class I or class III AAD to restore or maintain sinus rhythm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cryoballoon ablation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receive cryoballoon ablation to restore sinus rhythm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiarrhythmic drug including Propafenone, Sotalol, Dronedarone and Amiodarone</intervention_name>
    <description>Class I or III antiarrhythmic drug, including sotalol</description>
    <arm_group_label>Drug treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>cryoballoon ablation</intervention_name>
    <description>Pulmonary vein isolation by cryoballoon ablation using Medtronic Arctic Front Advance™ Cardiac CryoAblation Catheters (23mm and 28mm)</description>
    <arm_group_label>cryoballoon ablation group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documentation of symptomatic persistent AF: Defined as having a continuous episode&#xD;
             lasting longer than 7 days but less than 6 months documented by consecutive ECG&#xD;
             recordings OR Defined as having a continuous episode lasting longer than 7 days but&#xD;
             less than 6 months documented by an ECG recording and one doctor note indicating&#xD;
             patient had symptoms consistent with AF&#xD;
&#xD;
          -  Age 18 or older (or older than 18 if required by local law)&#xD;
&#xD;
          -  Structurally normal heart with LVEF ≥50%, interventricular septum thickness ≤ 12 mm,&#xD;
             and left atrial diameter &lt;46 mm (short axis) as obtained by transthoracic&#xD;
             echocardiography. •&#xD;
&#xD;
          -  Normal ECG parameters when measured in sinus rhythm (QRS width ≤120 ms in a 12-channel&#xD;
             surface ECG, QTc interval &lt;440 ms, and PQ interval ≤210 ms).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of AF treatment with class I or III antiarrhythmic drug, including sotalol,&#xD;
             with the intention to prevent an AF recurrence. However, patients pretreated with&#xD;
             above AAD for less than 7 days with the intention to convert an AF episode are&#xD;
             allowed.&#xD;
&#xD;
          -  left atrial ablation or surgical procedure (including left atrial appendage closures)&#xD;
&#xD;
          -  Presence or likely implant of a permanent pacemaker, biventricular pacemaker, loop&#xD;
             recorder, or any type of implantable cardiac defibrillator (with or without&#xD;
             biventricular pacing function) within 12 months&#xD;
&#xD;
          -  Presence of any pulmonary vein stents&#xD;
&#xD;
          -  Presence of any pre-existing pulmonary vein stenosis&#xD;
&#xD;
          -  Pre-existing hemidiaphragmatic paralysis&#xD;
&#xD;
          -  Presence of any cardiac valve prosthesis&#xD;
&#xD;
          -  +3 and +4 mitral valve regurgitation or stenosis&#xD;
&#xD;
          -  Any cardiac surgery, myocardial infarction, percutaneous coronary intervention (PCI) /&#xD;
             percutaneous transluminal coronary angioplasty (PTCA) or coronary artery stenting&#xD;
             which occurred during the 3 month interval preceding e consent date&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  New York Heart Association (NYHA) Class II, III or IV congestive heart failure&#xD;
&#xD;
          -  Primary pulmonary hypertension&#xD;
&#xD;
          -  Rheumatic heart disease&#xD;
&#xD;
          -  Thrombocytosis, thrombocytopenia&#xD;
&#xD;
          -  Any condition contraindicating chronic anticoagulation&#xD;
&#xD;
          -  Active systemic infection&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Cryoglobulinemia&#xD;
&#xD;
          -  Uncontrolled hyperthyroidism&#xD;
&#xD;
          -  Any cerebral ischemic event (strokes or transient ischemic attacks (TIAs)) which&#xD;
             occurred during the 6 month interval preceding the consent date&#xD;
&#xD;
          -  Any woman known to be pregnant or breastfeeding.&#xD;
&#xD;
          -  Life expectancy less than one year&#xD;
&#xD;
          -  Current or anticipated participation in any other clinical trial of a drug, device or&#xD;
             biologic during the duration of the study not pre-approved by Medtronic&#xD;
&#xD;
          -  Active intracardiac thrombus&#xD;
&#xD;
          -  Known drug or alcohol dependency&#xD;
&#xD;
          -  Unwilling or unable to comply fully with study procedures and follow-up&#xD;
&#xD;
          -  Significant Chronic Kidney Disease-estimated Glomerular Filtration Rate(CKD-eGFR)&#xD;
             &lt;30umol/L&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li-qun Wu, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li-qun Wu, MD,PhD</last_name>
    <phone>+8613801621534</phone>
    <email>wuliqun89@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yangyang Bao, MD,PhD</last_name>
    <phone>+8613301687572</phone>
    <email>575525677@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Li-qun Wu, MD,PhD</last_name>
      <phone>+8613801621534</phone>
      <email>wuliqun89@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yangyang Bao, MD,PhD</last_name>
      <phone>+8613301687572</phone>
      <email>575525677@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Li-qun Wu, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yangyang Bao, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cryoablation</keyword>
  <keyword>pulmonary vein isolation</keyword>
  <keyword>atrial fibrillation</keyword>
  <keyword>Anti-Arrhythmic Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
    <mesh_term>Sotalol</mesh_term>
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
    <mesh_term>Dronedarone</mesh_term>
    <mesh_term>Propafenone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

